The most important takeaway from the 2026 MPO Top 30 report is not embedded in any one transaction but rather the pattern among the ranked firms.
The conversation at FMMC mirrored some of the discussions taking place in deal rooms this year.
Medtech companies must assess where artificial intelligence creates value at each stage of the product lifecycle.
Watch Dave Sheppard give the 2026 ODT Forum State of the Industry. This session provides a comprehensive overview of the happenings within the orthopedic device manufacturing industry. Supply chain, M&A, and other related topics critical to both OEMs and their supply partners are covered.
Rewatch our webinar with Today’s Medical Developments as we explore the value impacts of AI in MedTech in 2026 for MedTech companies at all stages of growth – from start-up to scale-up including operational excellence through M&A Exit.
The $75 billion orthopedic market is growing, but pricing pressure throughout the supply chain is intensifying.
With the global environment for medical device manufacturing, cross-border deals are common and may provide for a unique definition for success.
When connected medical devices meet state-sponsored hackers, the C-suite owns the outcome.
Medtech executives or board members with an eye toward a future liquidity event should start building intrinsic value in their respective organizations now.
Capability-building medtech acquisitions are more relevant to the market than headline-grabbing transformational ones. Read more in our column, MedTech Mindset, in Today’s Medical Developments Magazine.